Comparison of Mirtazapine and Olanzapine on Nausea and Vomiting Following Anthracycline-Cyclophosphamide Chemotherapy Regimen in Patients with Breast Cancer

Document Type : Research article

Authors

1 Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 Department of Medical Oncology, Hematology and Bone Marrow Transplantation, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

3 Food Safety Research Center, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

4 Department of Psychiatry, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

5 Pharmacuetical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abstract

    We evaluated and compared the efficacy and safety of mirtazapine (MTZ) with olanzapine (OLP) for preventing chemotherapy-induced nausea and vomiting (CINV) following anthracycline plus cyclophosphamide (AC) regimen. Eligible participants were chemotherapy-naive early-stage breast cancer patients who were scheduled to undergo adjuvant AC. The patients were randomized to take oral MTZ or OLP in combination with aprepitant (A), dexamethasone (D), and granisetron (G), (ADG). The endpoints included rates of complete response (CR), complete control (CC), total control (TC), and adverse events during the acute, delayed, and overall phases in the two cycles of chemotherapy. The influence of CINV on the quality of life (QoL) was evaluated on day 6 of chemotherapy. Of 82 patients, 60 were randomized. In the first cycle, CR rates in cycle 1 were 83.3% and 76.6% during the acute period, 80% and 86.6% during the delayed period, and 66.6% and 63.3% during the overall period, for the ADG-M and ADG-O, respectively. High efficacy of both groups was maintained over 2 cycles. More patients in the ADG-M group noted minimal or no impact of CINV on daily life in cycle 2 (89.7% vs. 67.9%; p = 0.044). Incidence of somnolence and fatigue was more frequent with the olanzapine group. In this study, there was no substantial difference between mirtazapine and olanzapine in preventing CINV. Further large randomized trials are essential to demonstrate the anti-emetic effect of mirtazapine in chemotherapy.

Graphical Abstract

Comparison of Mirtazapine and Olanzapine on Nausea and Vomiting Following Anthracycline-Cyclophosphamide Chemotherapy Regimen in Patients with Breast Cancer

Keywords


  • Navari RM and Schwartzberg LS. The evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting. Onco Targets Ther. (2018) 11: 6459-78.
  • Yoodee J, Permsuwan U and Nimworapan M. Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. Rev. Oncol. Hematol. (2017) 112: 113-25.
  • Fahimi F, Khodadad K, Amini S, Naghibi F, Salamzadeh J and Baniasadi S. Evaluating the effect of zingiber officinalis on nausea and vomiting in patients receiving Cisplatin based regimens. J. Pharm. Res. (2011) 10: 379-84.
  • Ebrahimi M, Allahyari A, Ebrahimi M, Hesam H, Hosseini G, Karimi M, Rezaiean A and Kazemi MR. Effects of dietary honey and ardehcombination on chemotherapy-induced gastrointestinal and infectious complications in patients with acute myeloid leukemia: a double-blind randomized clinical trial. J. Pharm. Res. (2016) 5: 661-8.
  • Zhou J, Huang L, Jin S, XU C, Frey B, Ma H and Gaipal US. Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderately emetogenic chemotherapy: a systematic review and meta-analysis of randomized controlled trials. ESMO Open (2020) 5: e000621.
  • Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Somerfield MR and Lyman GH. Antiemetics: American society of clinical oncology clinical practice guideline update. Clin. Oncol. (2017) 35: 3240–61.
  • National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis – Version 3. (2018). Available from URL: www.nccn.org/patients.
  • Herrstedt J, Roila F, Warr D, Celio L, Navari RM, Hesketh PJ, Chan A and Aapro MS. 2016 Updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Care Cancer (2017) 25: 277–88.
  • Razvi Y, Chan S, McFarlane T, McKenzie E, Zaki P, DeAngelis C, Pidduck W, Bushehri A, Chow E and Jerzak KJ. ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Care Cancer (2019) 27: 87–95.
  • Wang XF, Feng Y, Chen Y, Gao BL and Han BH. A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Rep. (2014) 4: 4813.
  • Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM and Loprinizi CL. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Engl. J. Med. (2016) 375: 134–42.
  • Navari RM. Cancer patients at high risk for chemotherapy-induced nausea and vomiting prediction assessment/tools. Expert Rev. Quality Life Cancer Care (2017) 2: 102–8.
  • Navari RM. 5-HT3 receptors as important mediators of nausea and vomiting due to Chemotherapy. Biophys. Acta (2015) 1848: 2738–46.
  • Ng T, Hutton B and Clemons M. Chemotherapy-induced nausea and vomiting: time for more emphasis on nausea? Oncologist (2015) 20: 576-83.
  • Sanger GJ and Andrews PLR. A history of drug discovery for treatment of nausea and vomiting and the implications for future research. Pharmacol. (2018) 9: 913.
  • Chow R, Chiu L, Navari R, Passik S, Chiu N, Popovic M, Lam H, Pasetka M, Chow E and DeAngelis C. Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review. Care Cancer (2016) 24: 1001-3.
  • Kawazoe H, Uozumi R, Murakami A, Yamashita M, Kobayashi-Taguchi K, Kusakabe E, Yamasawa H, Yakushijin Y, Nakamura T and Kamei Y. Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study. Sci. Rep. (2018) 8: 16232.
  • Abe M, Kasamatsu Y, Kado N, Kuji S, Tanaka A, Takahashi N, Takekuma M, and Hirashima Y. Efficacy of olanzapine combined therapy for patients receiving highly emetogenic chemotherapy resistant to standard antiemetic therapy. Res. Int. (2015) 2015: 956785.
  • Tan L, Liu J, Liu X, Chen J, Yan Z, Yang H and Zhang D. Clinical research of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Exp. Clin. Cancer Res. (2009) 28: 131.
  • Chiu L, Chiu N, Chow R, Zhang L, Pasetka M, Stinson J, Lechner B, Pulenzas N, Verma S, Chow E and DeAngelis Carlo. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): A retrospective study. Palliat. Med. (2016) 5: 172-8.
  • Iihara H, Shimokawa M, Hayasaki Y, Fujita Y, Abe M, Takenaka M, Yamamoto S, Arai T, Sakurai M, Mori M, Nakamura K, Kado N, Murase S, Shimaoka Ri, Suzuki Akio and Morishige K. Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron, and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study. Oncol. (2020) 156: 629-35
  • Cao J, Ouyang Q, Wang S, Ragaz J, Wang X, Teng Y, Wang B, Wang Z, Zhang  J, Wang L, Wu  J, Shao Z and Hu  Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open-label, randomized, multicenter phase III trial. Invest. New Drugs (2020) 38: 507-14.
  • Omran HASA, Nasr DAM and Ali-eid HE. Effect of premedication with mirtazapine versus ondansetron on postoperative nausea and vomiting in breast surgery. J. Anaesth. (2011) 27: 135-9.
  • Bhattacharjee D, Doleman B, Lund J and Williams J. Mirtazapine for postoperative nausea and vomiting: systematic review, meta-analysis, and trial sequential analysis. Perianesth. Nurs. (2019) 34: 680-90
  • Kim SW, Shin IS, Kim JM, Kim YC, Kim KS, Kim KM, Yang SJ and Yoon JS. Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry Clin. Neurosci. (2008) 62:75-83.
  • Thompson DS. Mirtazapine for the treatment of depression and nausea in breast and gynecological oncology. Psychosomatics (2000) 41: 356-9.
  • Davis MP, Khawam E, Pozuelo L and Lagman R. Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. Expert Rev. Anticancer Ther. (2002) 2: 365-76.
  • Kast RE and Foley KF. Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. J. Cancer Care (2007) 16: 351-3
  • Riechelmann RP, Burman D, Tannock IF, Rodin G and Zimmermann C. Phase II trial of mirtazapine for cancer-related cachexia and anorexia. J. Hosp. Palliat. Care (2010) 27: 106-10.
  • Aslan S, Isik E and Cosar B. The effects of mirtazapine on sleep: a placebo-controlled, double-blind study in young healthy volunteers. Sleep (2002) 25: 677-9.
  • Kumar N, Barai S, Gambhir S and Rastogi N. Effect of mirtazapine on gastric emptying in patients with cancer-associated anorexia. Indian J. Palliat. Care (2017) 23: 335-7
  • Kast RE. Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy. Care Cancer (2001) 9: 469-70.
  • https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (Accessed on March 09, 2020).
  • Yeo W, Lau TK, Li L, Lai KT, Pang E, Cheung M, Chan VTC, Wong A, Soo WM, Yeung VT, Tse T, Lam DC, Yeung EW, Ng KP, Tang NL, Tong M, Suen JJ and Mo FK. A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients. Breast (2020) 50: 30-8.
  • Lindley CM, Hirsch JD, O'Neill CV, Transau MC, Gilbert CS and Osterhaus JT. Quality of life consequences of chemotherapy-induced emesis. Life Res. (1992) 1: 331–40
  • Martin AR, Pearson JD, Cai B, Elmer M, Horgan K and Lindley C. Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLI-E) with 5-day recall. Care Cancer (2003) 11: 522-7.
  • Tienchaiananda P, Nipondhkit W, Maneenil K, Sa-Nguansai S, Payapwattanawong S, Laohavinij S and Maneechavakajorn J. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide. Palliat. Med. (2019) 8: 372-80.
  • Roila F. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis.  Oncol. (1995) 6: 805–10.
  • Italian Group for Antiemetic Research. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Care Cancer. (2000) 8: 229-32.
  • Stimmel GL, Dopheide JA and Stahl SM. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy (1997) 17: 10-21.
  • Chang FL, Ho ST and Sheen MJ. Efficacy of mirtazapine in preventing intrathecal morphine-induced nausea and vomiting after orthopedic surgery. Anaesthesia (2010) 65: 1206-11.
  • Roscoe JA, Morrow GR, Aapro MS, Molassiotis A and Olver I. Anticipatory nausea and vomiting. Care Cancer (2011) 19: 1533-8.
  • Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. Engl. J. Med. (2000) 342: 1554-9.
  • Navari RM, Einhorn LH, Loehrer PJ Sr, Passik SD, Vinson J, McClean J, Chowhan N, Hanna NH and Johnson CS. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Care Cancer (2007) 15: 1285-91.
  • Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ and Skobieranda F. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. Clin. Oncol. (2005) 23: 2822-30.
  • Janelsins MC, Tejani MA, Kamen C, Peoples AR, Mustian KM and Morrow GR. Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Opin. Pharmacother. (2011) 4: 757-66.
  • Aapro M. CINV: still troubling patients after all these years. Care Cancer (2018) 26: 5-9.
  • Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W, Koh J, Yeung WK, Kwan WH, Lee KK, Mok TS, Poon AN, Lam KC, Hui EK and Zee B. A randomized study of aprepitant, ondansetron, and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res. Treat. (2009) 113: 529-35.
  • Navari RM, Gray SE and Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. Support. Oncol. (2011) 9: 188-95.
  • Economos G, Lovell N, Johnston A and Hagginson IJ. What is the evidence for mirtazapine in treating cancer-related symptomatology? A systematic review. Care Cancer (2020) 28: 1597-606.
  • Abe M, Hirashima Y, Kasamatsu Y, Kado N, Komeda S, Kuji S, Tanaka A, Takahashi N, Takekuma M, Hihara H, Ichikawa Y, Itonaga Y, Hirakawa T, Nasu K, Miyagi K, Murakami J and Ito K. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial. Care Cancer (2016) 24: 675-82.
  • Liu J, Tan L, Zhang H, Li H, Liu X, Yan Z, Chen J, Yang H and Zhang D. QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist. J. Cancer Care (Engl). (2015) 24: 436-43.
  • Passik SD, Navari RM, Jung SH, Nagy C, Vinson J, Kirsh KL and Loehrer P. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: A Hoosier Oncology Group study. Cancer Invest. (2004) 22: 383-8.
  • Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, Hoshina Y, Sakata Y, TY Takahashi, Nakashima K, Nakao M, Takei D, Zenda S,  Mizukami K, Iwasa S, Sakurai M, Yamamoto N and  Ohe Y. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Ancol. (2019) 21: 242-9.
  • Aapro M, Fabi A, Nolè F, Medici M, Steger G, Bachmann C, Roncoroni S and Roila F. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Oncol. (2010) 21: 1083-8.
  • Martin AR, Carides AD, Pearson JD, Horgan K, Elmer M, Schmidt C, Cai B, Chawla SP and Grunberg SM. Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. J. Cancer (2003) 39: 1395-401.